"Pharmaceutical headlines" DRGs and the next city 115 national harvest varieties ushered in great good

(2020/10/20) AstraZenecon two drugs approved by CHMP for heart failure and slow-blocking lung; talk about the year of anti-epidemic medicine mergers and acquisitions; DRGs next city 115 varieties of national harvest ushered in a big good auxiliary drug again to meet the blow; talk about the year of anti-epidemic pharmaceutical mergers and acquisitions ... (Click on the title, available in the original article) "Pharmaceutical 1st Time" AstraZeneca two drugs approved by CHMP for heart failure and chronic pulmonary resistance October 19, AstraZeneca announced Forxiga (dapagliflozin, Dagliflozin, Daglile net) expansion of adaptation The disease has been recommended by the European Medicines Agency (EMA) Human Medicines Council (CHMP) for marketing in the European Union (EU) for the treatment of adult patients with symptomatic chronic heart failure (HFrEF), whether or not they have type 2 diabetes (T2D) and a reduced blood score.
At the same time, the company Trixeo Aerosphere (Fumaric Acid Fomotro/Brominated Paramonium Bromide/Budinide) is also recommended by CHMP for EU marketing for the treatment of adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) in combination with inadequate inhalation of corticosteroids (ICS) and long-acting beta-2-inflammatory agents (LABA) or INA and long-acting venom-alkali antagonists.
headline: AstraZeneta is good.
the five scenarios of how the pharmaceutical industry digitally sinks medical health as an important industry related to the national economy and people's livelihood, digital technology will bring disruptive innovation and reshape the entire medical and health industry ecology.
In the concept of medical health, medicine is the pillar of building a medical and health ecology, and the size of China's pharmaceutical market has grown from 955.5 billion yuan in 2012 to 215 billion yuan in 2020, with a compound annual growth rate of 10.7%.
pharmaceutical industry must follow the trend, adapt to the trend of digital development, take the initiative to seek new mutations, and better contribute to the development of the medical and health industry.
headlines: Digital patient management improves patient compliance.
"E drug manager" DRGs and the next city 115 national varieties ushered in a big good auxiliary drug and then face the attack yesterday, the Health Insurance Bureau issued "on the issuance of the total regional points law budget and pay according to the disease value of the pilot work programme notice", which means that DRGs will soon be the next city.
, a senior DRGs researcher, said, "This time the document is a set rule, which is equivalent to laying the ground stone for a full pilot next year."
" From 2018, when the Health Care Administration issued the Notice on the Declaration of National Pilots for Paying by Groups Related to Disease Diagnosis (No. 27), the DRGs Pay Pilot was officially taken over by the Health Insurance Administration, which published a list of 30 pilot cities by 2019, followed by the release of the CHS-DRG Subgroup Program to complete the standard action.
: The biggest difference between DIP and DRGs is that they are grouped differently.
CP hI Pharmaceuticals Online talks about the anti-epidemic years of pharmaceutical mergers and acquisitions in recent years, some well-known pharmaceutical companies such as Lilly, Roche, Amgen, Sanofi and other mergers and acquisitions cases.
as recently as 2019, pharmaceutical mergers and acquisitions have been very active, with more than $10 billion in pharmaceutical mergers and acquisitions in five cases.
a few days ago, Bristol Myers' $13bn acquisition of MyoKardia, a drugmaker known for developing heart drugs, has raised concerns in the pharmaceutical industry.
: Research and acquisitions are the eternal topics for pharmaceutical companies.